Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Gemcitabine/Nab-Paclitaxel in Metastatic PDAC
NCT02562898Phase 2Completed
- Start
- Oct 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in pancreatic adenocarcinoma (PDAC). Started Oct 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02562898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562898.